97 related articles for article (PubMed ID: 4053061)
1. Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma.
Sears HF; Herlyn D; Steplewski Z; Koprowski H
Cancer Res; 1985 Nov; 45(11 Pt 2):5910-3. PubMed ID: 4053061
[TBL] [Abstract][Full Text] [Related]
2. Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma.
Sears HF; Herlyn D; Steplewski Z; Koprowski H
J Biol Response Mod; 1984; 3(2):138-50. PubMed ID: 6374043
[TBL] [Abstract][Full Text] [Related]
3. Antiidiotype antibodies in cancer patients receiving monoclonal antibody to carcinoembryonic antigen.
Traub UC; DeJager RL; Primus FJ; Losman M; Goldenberg DM
Cancer Res; 1988 Jul; 48(14):4002-6. PubMed ID: 3289737
[TBL] [Abstract][Full Text] [Related]
4. A phase I clinical trial of murine monoclonal antibody D612 in patients with metastatic gastrointestinal cancer.
Saleh MN; Khazaeli MB; Grizzle WE; Wheeler RH; Lawson S; Liu T; Russel C; Meredith R; Schlom J; LoBuglio AF
Cancer Res; 1993 Oct; 53(19):4555-62. PubMed ID: 8402627
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II trial of combined 131I anti-CEA monoclonal antibody and hyperthermia in patients with advanced colorectal adenocarcinoma.
Mittal BB; Zimmer MA; Sathiaseelan V; Benson AB; Mittal RR; Dutta S; Rosen ST; Spies SM; Mettler JM; Groch MW
Cancer; 1996 Nov; 78(9):1861-70. PubMed ID: 8909304
[TBL] [Abstract][Full Text] [Related]
6. Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer.
Wong JY; Chu DZ; Williams LE; Yamauchi DM; Ikle DN; Kwok CS; Liu A; Wilczynski S; Colcher D; Yazaki PJ; Shively JE; Wu AM; Raubitschek AA
Clin Cancer Res; 2004 Aug; 10(15):5014-21. PubMed ID: 15297402
[TBL] [Abstract][Full Text] [Related]
7. Immune function of patients with gastrointestinal carcinoma after treatment with multiple infusions of monoclonal antibody 17.1A.
Blottière HM; Maurel C; Douillard JY
Cancer Res; 1987 Oct; 47(19):5238-41. PubMed ID: 3621210
[TBL] [Abstract][Full Text] [Related]
8. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma.
Divgi CR; Scott AM; Dantis L; Capitelli P; Siler K; Hilton S; Finn RD; Kemeny N; Kelsen D; Kostakoglu L
J Nucl Med; 1995 Apr; 36(4):586-92. PubMed ID: 7699446
[TBL] [Abstract][Full Text] [Related]
9. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
Wong JY; Thomas GE; Yamauchi D; Williams LE; Odom-Maryon TL; Liu A; Esteban JM; Neumaier M; Dresse S; Wu AM; Primus FJ; Shively JE; Raubitschek AA
J Nucl Med; 1997 Dec; 38(12):1951-9. PubMed ID: 9430476
[TBL] [Abstract][Full Text] [Related]
11. Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies.
Juweid M; Swayne LC; Sharkey RM; Dunn R; Rubin AD; Herskovic T; Goldenberg DM
Gynecol Oncol; 1997 Dec; 67(3):259-71. PubMed ID: 9441773
[TBL] [Abstract][Full Text] [Related]
12. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.
Börjesson PK; Postema EJ; Roos JC; Colnot DR; Marres HA; van Schie MH; Stehle G; de Bree R; Snow GB; Oyen WJ; van Dongen GA
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3961S-72S. PubMed ID: 14506195
[TBL] [Abstract][Full Text] [Related]
13. Initial trial use of murine monoclonal antibodies as immunotherapeutic agents for gastrointestinal adenocarcinoma.
Sears HF; Herlyn D; Steplewski Z; Koprowski H
Hybridoma; 1986 Jul; 5 Suppl 1():S109-15. PubMed ID: 3488949
[No Abstract] [Full Text] [Related]
14. Phase I clinical trial of the chimeric monoclonal antibody (c30.6) in patients with metastatic colorectal cancer.
Ward RL; Packham D; Smythe AM; Murray J; Anderson-Stewart P; Kitchen N; Muirhead R; Phillips P; Gray P; Bigg-Wither G; Prabakaran K; Freund J; Fullham M; Rule M; Dalley D; Meagher A; Hawkins NJ; Smith GM
Clin Cancer Res; 2000 Dec; 6(12):4674-83. PubMed ID: 11156219
[TBL] [Abstract][Full Text] [Related]
15. Hepatic transcatheter arterial chemoembolization alternating with systemic protracted continuous infusion 5-fluorouracil for gastrointestinal malignancies metastatic to liver: a phase II trial of the Puget Sound Oncology Consortium (PSOC 1104).
Bavisotto LM; Patel NH; Althaus SJ; Coldwell DM; Nghiem HV; Thompson T; Storer B; Thomas CR
Clin Cancer Res; 1999 Jan; 5(1):95-109. PubMed ID: 9918207
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of murine monoclonal antibody D612 combined with recombinant human monocyte colony-stimulating factor (rhM-CSF) in patients with metastatic gastrointestinal cancer.
Saleh MN; Khazaeli MB; Wheeler RH; Bucy RP; Liu T; Everson MP; Munn DH; Schlom J; LoBuglio AF
Cancer Res; 1995 Oct; 55(19):4339-46. PubMed ID: 7671245
[TBL] [Abstract][Full Text] [Related]
17. Repeated administration of a F(ab')2 fragment of an anti-tumor necrosis factor alpha monoclonal antibody in patients with severe sepsis: effects on the cardiovascular system and cytokine levels.
Boekstegers P; Weidenhöfer S; Zell R; Pilz G; Holler E; Ertel W; Kapsner T; Redl H; Schlag G; Kaul M
Shock; 1994 Apr; 1(4):237-45. PubMed ID: 7735957
[TBL] [Abstract][Full Text] [Related]
18. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR.
Juweid ME; Hajjar G; Stein R; Sharkey RM; Herskovic T; Swayne LC; Suleiman S; Pereira M; Rubin AD; Goldenberg DM
J Nucl Med; 2000 Jan; 41(1):93-103. PubMed ID: 10647610
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies specific immunotherapy of gastrointestinal tumors.
Douillard JY; Lehur PA; Vignoud J; Blottière H; Maurel C; Thedrez P; Kremer M; Le Mevel B
Hybridoma; 1986 Jul; 5 Suppl 1():S139-49. PubMed ID: 3527945
[TBL] [Abstract][Full Text] [Related]
20. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.
Brown MT; Coleman RE; Friedman AH; Friedman HS; McLendon RE; Reiman R; Felsberg GJ; Tien RD; Bigner SH; Zalutsky MR; Zhao XG; Wikstrand CJ; Pegram CN; Herndon JE; Vick NA; Paleologos N; Fredericks RK; Schold SC; Bigner DD
Clin Cancer Res; 1996 Jun; 2(6):963-72. PubMed ID: 9816257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
